DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the TORRENT PHARMACEUTICALS L (TORNTPHARM) share price today?

TORRENT PHARMACEUTICALS L (TORNTPHARM) is trading at ₹4,763 on the NSE, down 4.50% on the day. Source: DocStoX.

What is the PE ratio of TORRENT PHARMACEUTICALS L?

TORRENT PHARMACEUTICALS L has a price-to-earnings (PE) ratio of 74.5 in the Healthcare sector.

What is the market capitalisation of TORRENT PHARMACEUTICALS L?

TORRENT PHARMACEUTICALS L has a market capitalisation of approximately ₹1,61,243 crore.

TORRENT PHARMACEUTICALS L

F&O

TORNTPHARM·NSE·Healthcare

₹4,763.00▼ -224.60 (-4.50%)

Healthcare · Pharmaceuticals

High-quality returns — 27% on equity

NIFTY NEXT 50NIFTY 100NIFTY 200

Day₹4695.10

₹4932.90

52W₹3468

₹508680%

Open

₹4915.40

High

₹4932.90

Low

₹4695.10

Prev Close

₹4987.60

Volume

13.97L

VWAP

₹4783.02

Snapshot

Key fundamentals

Market Cap

₹1.61L Cr

P/E Ratio

74.52Expensive

P/B Ratio

19.76

EPS

₹63.92

Book Value

₹248.00

ROE

27.40%Strong

ROCE

15.00%Decent

Dividend Yield

0.78%

Debt / Equity

1.79High

Face Value

₹5.00

52W High

₹5085.80

52W Low

₹3468.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹428

▼ 91.0%downside

Trading at ₹4,763 — 91% above our estimate

BearFair valueBull

₹364₹428₹597

/100

Business quality — Solid

Growth 66Profitability 87Efficiency 18Valuation 5

Plain English

Our view

High-quality returns — 27% on equity
Strong returns on equity (27%)
High leverage — debt exceeds 1.5× equity

Strengths

Strong returns on equity (27%)
Profit growing 20% a year
Promoters hold a controlling stake

Risks

High leverage — debt exceeds 1.5× equity
Expensive — trades at 75× earnings
Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

27% ROE fading to 14% over ~10 yrs, on ₹248 book

₹381

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹597

Analyst target

No analyst coverage

—

Blended fair value₹428

What the numbers say

Investment thesis

Bull case

Strong returns on equity (27%)
Profit growing 20% a year
Promoters hold a controlling stake

Bear case

High leverage — debt exceeds 1.5× equity
Expensive — trades at 75× earnings
Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

74.5Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

27.4%Strong

Above 15% is considered healthy for Indian equities

ROCE

15.0%Decent

Above 18% means capital is working hard

Debt/Eq

1.79High

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹1.61L Cr

P/B

19.76

EPS

₹63.92

Div Yield

0.78%

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Expensive

P/E 74.5×

Growth

Steady

+13% rev CAGR

Profitability

Excellent

27.4% ROE

Financial health

Leveraged

D/E 1.79

Momentum

N/A

No technicals

Today

Trading activity

Delivery %51.6%

Turnover₹66815.38L Cr

Trades94,290

VWAP₹4783.02

Face value₹5.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+13.3%

+11.8%

10Y

+7.7%

Profit

+19.8%

+11.3%

10Y

+2.1%

EPS

+20.2%

+11.6%

10Y

+2.2%

Profile

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%
Company has been maintaining a healthy dividend payout of 57.8%

Watch-outs

Cons

Stock is trading at 19.8 times its book value
The company has delivered a poor sales growth of 11.8% over past five years.
Company might be capitalizing the interest cost

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

68%

Promoter

Promoters

68.3%0.00

Public

4.1%+0.09

FII / FPI

16.2%+0.05

DII

9.1%-0.08

Others

2.3%

Total shareholders

83,811+7,597 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter68.31%

FII16.18%

DII9.06%

Public4.12%

Others2.33%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

F&O